Rafic Beydoun
YOU?
Author Swipe
View article: Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Open
Background Several KRASG12D inhibitors (KRASG12Di) are under clinical evaluation for pancreatic ductal adenocarcinoma (PDAC). However, as seen with other first generation KRAS inhibitors, resistance may limit their long-term efficacy, nece…
View article: Multi-modal AI for comprehensive breast cancer prognostication
Multi-modal AI for comprehensive breast cancer prognostication Open
Treatment selection in breast cancer is guided by molecular subtypes and clinical characteristics. However, current tools including genomic assays lack the accuracy required for optimal clinical decision-making. We developed a novel artifi…
View article: The Janus kinase 1 is critical for pancreatic cancer initiation and progression
The Janus kinase 1 is critical for pancreatic cancer initiation and progression Open
Interleukin-6 (IL-6)-class inflammatory cytokines signal through the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and promote the development of pancreatic ductal adenocarcinoma (PDAC); howeve…
View article: Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Table S1 shows the sequences of primers used for RT-qPCR
View article: Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S5 shows effects of KPT9274 and MRTX849 combinations on the proliferation of KRAS4BG12C and KRAS4BG12D MEFs
View article: Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this iss…
View article: Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S1 shows chemical structure of KPT9274
View article: Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S4 shows effects of KPT9274 and KRAS G12Ci combinations on the proliferation of HPAC and MIA-AMG-R cells
View article: Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S5 shows effects of KPT9274 and MRTX849 combinations on the proliferation of KRAS4BG12C and KRAS4BG12D MEFs
View article: Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S1 shows chemical structure of KPT9274
View article: Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model Open
Background The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effec…
View article: Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S2 shows PAK4-KRAS synthetic lethal interaction identified using the Slorth database
View article: Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S2 shows PAK4-KRAS synthetic lethal interaction identified using the Slorth database
View article: Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S7 shows the quantification of spheroid disintegration assay data shown in Figure 3C
View article: Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this iss…
View article: Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S3 shows synergistic inhibition of NCI-H2122 cell proliferation by combinations of KPT9274 and KRAS G12C inhibitors
View article: Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Table S1 shows the sequences of primers used for RT-qPCR
View article: Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S4 shows effects of KPT9274 and KRAS G12Ci combinations on the proliferation of HPAC and MIA-AMG-R cells
View article: Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S6 shows colony counts from the colony formation assay data shown in Figure 3A
View article: Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S6 shows colony counts from the colony formation assay data shown in Figure 3A
View article: Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S3 shows synergistic inhibition of NCI-H2122 cell proliferation by combinations of KPT9274 and KRAS G12C inhibitors
View article: Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S7 shows the quantification of spheroid disintegration assay data shown in Figure 3C
View article: Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i> G12C-Mutant Pancreatic and Lung Cancers
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i> G12C-Mutant Pancreatic and Lung Cancers Open
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this iss…
View article: Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality- dataset 1
Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality- dataset 1 Open
Background Colorectal cancers are the fourth most diagnosed cancer and the second leading cancer in number of deaths. Many clinical variables, pathological features, and genomic signatures are associated with patient risk, but reliable pat…
View article: Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality- dataset 2
Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality- dataset 2 Open
Background Colorectal cancers are the fourth most diagnosed cancer and the second leading cancer in number of deaths. Many clinical variables, pathological features, and genomic signatures are associated with patient risk, but reliable pat…
View article: Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality
Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality Open
BACKGROUND: Colorectal cancers are the fourth most diagnosed cancer and the second leading cancer in number of deaths. Many clinical variables, pathological features, and genomic signatures are associated with patient risk, but reliable pa…
View article: Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers Open
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and…
View article: Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers Open
Supplementary Figure 1. XPO1-KRAS synthetic lethal interaction identified using the Slorth database. Supplementary Figure 2. KRAS WT, KRAS G12D and KRAS G12V MEF cell lines were refractory to growth inhibition by selinexor or MRTX1257 or t…